Melanotan II (MTII) infusion reduces food intake but fails to reverse diabetes in NPY-deficient mice.
Background
The central melanocortin 4 receptor (MC4R) is crucial for leptin's anorexogenic, antidiabetic, and cardiovascular actions. However, chronic MC4R stimulation often fails to fully replicate leptin's broad effects. Neuropeptide Y (NPY), a potent orexigenic and metabolic regulator, exerts opposing effects to MC4R on cardiovascular and metabolic functions. This study investigated whether NPY's presence offsets the long-term benefits of MC4R activation, particularly in the context of diabetes and its associated metabolic dysregulation.
Study Design
Researchers implanted telemetry probes in wild-type (WT) and NPY-deficient (NPY-/-) mice to continuously monitor mean arterial pressure (MAP) and heart rate (HR). Following a recovery and baseline period, mice received a 7-day intravenous infusion of the MC3/4R agonist melanotan II (MTII, 120 μg·kg-1·day-1 iv), followed by a recovery period. To assess antidiabetic effects, a separate cohort of WT and NPY-/- mice had diabetes induced with streptozotocin (STZ) one week prior to baseline measurements, and the same MTII protocol was applied. Food intake, MAP, HR, blood glucose, and body weight were primary endpoints.
Results
At baseline, NPY-/- mice exhibited slightly higher food intake (4.3 ± 0.2 g/day) compared to WT mice (3.4 ± 0.2 g/day), and a higher heart rate (567 ± 14 beats/min vs. 522 ± 13 beats/min). Chronic MTII infusion effectively reduced food intake in both WT and NPY-/- groups. However, transient increases in MAP and HR were observed exclusively in WT mice, peaking at 11 ± 3 mmHg and 126 ± 13 beats/min, respectively. This cardiovascular response was absent in NPY-/- mice. In the diabetic model, STZ induced similar hyperphagia, hyperglycemia, and weight loss in both WT and NPY-/- mice. > Crucially, chronic MTII treatment did not reverse these STZ-induced diabetic symptoms in either wild-type or NPY-deficient mice, indicating NPY deficiency does not amplify MC4R's antidiabetic effects.
Key Findings
- Chronic MTII infusion reduced food intake in both WT and NPY-deficient mice.
- Transient increases in MAP (11 ± 3 mmHg) and HR (126 ± 13 beats/min) occurred only in WT mice during MTII infusion.
- NPY-deficient mice had slightly higher baseline food intake (4.3 ± 0.2 g/day) and HR (567 ± 14 beats/min).
- Chronic MTII did not reverse STZ-induced hyperphagia, hyperglycemia, or weight loss in diabetic mice.
- NPY deficiency did not amplify the antidiabetic effects of MC4R activation.
Why It Matters
This research suggests that NPY deficiency does not enhance the antidiabetic or long-term cardiovascular benefits of MC4R activation. For individuals exploring MC4R agonists like MTII for metabolic or appetite control, this indicates that NPY's absence alone may not unlock broader therapeutic potential, especially in the context of established diabetes. The differential cardiovascular response (transient MAP/HR increase only in WT mice) highlights NPY's role in modulating MC4R's acute cardiovascular effects. Further research is needed to identify other pathways that might be offsetting MC4R's full leptin-mimetic potential, particularly for translating these findings into more effective antidiabetic strategies.
melanotan-ii
mc4r-agonist
appetite
blood-glucose
blood-pressure
npy